EVO logo

Evotec SE

EVO
Healthcare|Drug Manufacturers - Specialty & Generic|DE
$1.69
-0.09 (-4.79%)
Tangible Book / Share
$1.80
Cash / Share
$1.18
Next Earnings Report
Apr 14, 2027
EPS est. -$0.15 · Revenue est. $175.0M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (2)

Apr 2027
Est. completion
P1Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults
NCT06943378n=104
Dec 2032
Est. completion
Chronic Kidney Diseases
National Unified Renal Translation Research Enterprise - Chronic Kidney Disease
NCT04084145n=3,004

Recent Press Releases

Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Nov 5, 2026 · Business Wire
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
Nov 5, 2026 · PRNewsWire
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Nov 4, 2026 · Business Wire
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
Oct 29, 2026 · PRNewsWire
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Oct 15, 2026 · PRNewsWire
Evotec Announces Chief Scientific Officer Transition
Sep 29, 2026 · PRNewsWire
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Sep 23, 2026 · Business Wire
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Sep 9, 2026 · PRNewsWire
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Sep 8, 2026 · Business Wire
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Sep 2, 2026 · PRNewsWire

SEC Filings (45)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 20266-KForeign issuer reportDocumentIndex
Oct 15, 20266-KForeign issuer reportDocumentIndex
Oct 14, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 14, 20266-KForeign issuer reportDocumentIndex
Sep 29, 20266-KForeign issuer reportDocumentIndex
Sep 9, 20266-KForeign issuer reportDocumentIndex
Aug 13, 20266-KForeign issuer reportDocumentIndex
Jul 14, 20266-KForeign issuer reportDocumentIndex
Jun 30, 20266-KForeign issuer reportDocumentIndex
Jun 17, 20266-KForeign issuer reportDocumentIndex
May 6, 20266-KForeign issuer reportDocumentIndex
May 1, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Apr 30, 20266-KForeign issuer reportDocumentIndex
Apr 24, 20266-KForeign issuer reportDocumentIndex
Apr 8, 20266-KForeign issuer reportDocumentIndex
Apr 8, 202620-FAnnual report (foreign)DocumentIndex
Apr 7, 20266-KForeign issuer reportDocumentIndex
Apr 6, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 30, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Mar 10, 20266-KForeign issuer reportDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 16, 20266-KForeign issuer reportDocumentIndex
Jan 13, 20266-KForeign issuer reportDocumentIndex
Jan 8, 20266-KForeign issuer reportDocumentIndex
Jan 6, 20266-KForeign issuer reportDocumentIndex
Jan 2, 20266-KForeign issuer reportDocumentIndex
Jan 2, 20266-KForeign issuer reportDocumentIndex
Dec 8, 20256-KForeign issuer reportDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 6, 20256-KForeign issuer reportDocumentIndex
Nov 5, 20256-KForeign issuer reportDocumentIndex
Nov 5, 20256-KForeign issuer reportDocumentIndex
Oct 29, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 13, 20256-KForeign issuer reportDocumentIndex
Jul 30, 20256-KForeign issuer reportDocumentIndex
Jul 21, 20256-KForeign issuer reportDocumentIndex
Jun 3, 20256-KForeign issuer reportDocumentIndex
May 6, 20256-KForeign issuer reportDocumentIndex
Apr 17, 202520-FAnnual report (foreign)DocumentIndex